Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425–30.
Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002;110(3):285–8.
Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem. 2007;40(9–10):575–84.
Cole SL, Vassar R. Isoprenoids and Alzheimer’s disease: a complex relationship. Neurobiol Dis. 2006;22(2):209–22.
Eckert GP, Hooff GP, Strandjord DM, Igbavboa U, Volmer DA, Muller WE, et al. Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients. Neurobiol Dis. 2009;35(2):251–7.
Fonseca AC, Resende R, Oliveira CR, Pereira CM. Cholesterol and statins in Alzheimer’s disease: current controversies. Exp Neurol. 2010;223(2):282–93.
Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9(1):10–9.
Mijimolle N, Velasco J, Dubus P, Guerra C, Weinbaum CA, Casey PJ, et al. Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. Cancer Cell. 2005;7(4):313–24.
Swanson KM, Hohl RJ. Anti-cancer therapy: targeting the mevalonate pathway. Curr Cancer Drug Targets. 2006;6(1):15–37.
Nürenberg G, Volmer DA. The analytical determination of isoprenoid intermediates from the mevalonate pathway. Anal Bioanal Chem. 2012;402(2):671–85.
Saisho Y, Morimoto A, Umeda T. Determination of farnesyl pyrophosphate in dog and human plasma by high-performance liquid chromatography with fluorescence detection. Anal Biochem. 1997;252(1):89–95.
Hooff GP, Volmer DA, Wood WG, Muller WE, Eckert GP. Isoprenoid quantitation in human brain tissue: a validated HPLC-fluorescence detection method for endogenous farnesyl- (FPP) and geranylgeranylpyrophosphate (GGPP). Anal Bioanal Chem. 2008;392(4):673–80.
Hooff GP, Patel N, Wood WG, Muller WE, Eckert GP, Volmer DA. A rapid and sensitive assay for determining human brain levels of farnesyl- (FPP) and geranylgeranylpyrophosphate (GGPP) and transferase activities using UHPLC-MS/MS. Anal Bioanal Chem. 2010;398(4):1801–8.
Henneman L, van Cruchten AG, Denis SW, Amolins MW, Placzek AT, Gibbs RA, et al. Detection of nonsterol isoprenoids by HPLC-MS/MS. Anal Biochem. 2008;383(1):18–24.
Henneman L, van Cruchten AG, Kulik W, Waterham HR. Inhibition of the isoprenoid biosynthesis pathway; detection of intermediates by UPLC-MS/MS. Biochim Biophys Acta. 2011;1811(4):227–33.
Ramanathan R, Jemal M, Ramagiri S, Xia YQ, Humpreys WG, Olah T, et al. It is time for a paradigm shift in drug discovery bioanalysis: from SRM to HRMS. J Mass Spectrom. 2011;46(6):595–601.
Bruce SJ, Rochat B, Beguin A, Pesse B, Guessous I, Boulat O, et al. Analysis and quantification of vitamin D metabolites in serum by ultra-performance liquid chromatography coupled to tandem mass spectrometry and high-resolution mass spectrometry—a method comparison and validation. Rapid Commun Mass Spectrom. 2013;27(1):200–6.
Fedorova G, Randak T, Lindberg RH, Grabic R. Comparison of the quantitative performance of a Q-Exactive high-resolution mass spectrometer with that of a triple quadrupole tandem mass spectrometer for the analysis of illicit drugs in wastewater. Rapid Commun Mass Spectrom. 2013;27(15):1751–62.
Grund B, Marvin L, Rochat B. Quantitative performance of a quadrupole-orbitrap-MS in targeted LC-MS determinations of small molecules. J Pharm Biomed Anal. 2016;124:48–56.
Kaufmann A, Butcher P, Maden K, Walker S, Widmer M. Comprehensive comparison of liquid chromatography selectivity as provided by two types of liquid chromatography detectors (high resolution mass spectrometry and tandem mass spectrometry): “where is the crossover point?”. Anal Chim Acta. 2010;673(1):60–72.
Dahmane E, Boccard J, Csajka C, Rudaz S, Decosterd L, Genin E, et al. Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology. Anal Bioanal Chem. 2014;406(11):2627–40.
Leis HJ, Fauler G, Windischhofer W. Enantioselective quantitative analysis of amphetamine in human plasma by liquid chromatography/high-resolution mass spectrometry. Anal Bioanal Chem. 2014;406(18):4473–80.
Fung EN, Xia YQ, Aubry AF, Zeng J, Olah T, Jemal M. Full-scan high resolution accurate mass spectrometry (HRMS) in regulated bioanalysis: LC-HRMS for the quantitation of prednisone and prednisolone in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(27):2919–27.
Plumb RS, Fujimoto G, Mather J, Potts WB, Rainville PD, Ellor NJ, et al. Comparison of the quantification of a therapeutic protein using nominal and accurate mass MS/MS. Bioanalysis. 2012;4(5):605–15.
Morin LP, Mess JN, Garofolo F. Large-molecule quantification: sensitivity and selectivity head-to-head comparison of triple quadrupole with Q-TOF. Bioanalysis. 2013;5(10):1181–93.
Mekhssian K, Mess JN, Garofolo F. Application of high-resolution MS in the quantification of a therapeutic monoclonal antibody in human plasma. Bioanalysis. 2014;6(13):1767–79.
Kellie JF, Kehler JR, Szapacs ME. Application of high-resolution MS for development of peptide and large-molecule drug candidates. Bioanalysis. 2016;8(3):169–77.
Jones BR, Schultz GA, Eckstein JA, Ackermann BL. Surrogate matrix and surrogate analyte approaches for definitive quantitation of endogenous biomolecules. Bioanalysis. 2012;4(19):2343–56.
FDA (2013) Guidance for Industry. Bioanalytical method validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf
Sugimoto H, Kakehi M, Jinno F. Bioanalytical method for the simultaneous determination of d- and l-serine in human plasma by LC/MS/MS. Anal Biochem. 2015;487:38–44.
Sugimoto H, Kakehi M, Jinno F. Method development for the determination of D- and L-isomers of leucine in human plasma by high-performance liquid chromatography tandem mass spectrometry and its application to animal plasma samples. Anal Bioanal Chem. 2015;407(26):7889–98.
Sugimoto H, Kakehi M, Satomi Y, Kamiguchi H, Jinno F. Method development for the determination of 24S-hydroxycholesterol in human plasma without derivatization by high-performance liquid chromatography with tandem mass spectrometry in atmospheric pressure chemical ionization mode. J Sep Sci. 2015;38(20):3516–24.
Arnold ME, Booth B, King L, Ray C. Workshop Report: Crystal City VI—Bioanalytical Method Validation for Biomarkers. AAPS J. 2016;18:1366–72.
Van den Eede N, Neels H, Jorens PG, Covaci A. Analysis of organophosphate flame retardant diester metabolites in human urine by liquid chromatography electrospray ionisation tandem mass spectrometry. J Chromatogr A. 2013;1303:48–53.
Calvano CD, Jensen ON, Zambonin CG. Selective extraction of phospholipids from dairy products by micro-solid phase extraction based on titanium dioxide microcolumns followed by MALDI-TOF-MS analysis. Anal Bioanal Chem. 2009;394(5):1453–61.
Gonzalvez A, Preinerstorfer B, Lindner W. Selective enrichment of phosphatidylcholines from food and biological matrices using metal oxides as solid-phase extraction materials prior to analysis by HPLC-ESI-MS/MS. Anal Bioanal Chem. 2010;396(8):2965–75.
Tong H, Holstein SA, Hohl RJ. Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. Anal Biochem. 2005;336(1):51–9.
Takami T, Fang Y, Zhou X, Jaiseng W, Ma Y, Kuno T. A genetic and pharmacological analysis of isoprenoid pathway by LC-MS/MS in fission yeast. PLoS One. 2012;7(11):e49004.
Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res. 2006;23(2):312–28.